초록 ▼

Nitric oxide donor compounds of the formula: are provided. In the formula, R is (CH2)n,wherein n ranges from 1 to 8 and wherein each hydrogen atom on the alkylene group and on the phenyl groups can optionally be replaced by a substituent selected from the group consisting of alkyl, cycloalkyl, hete

Nitric oxide donor compounds of the formula: are provided. In the formula, R is (CH2)n,wherein n ranges from 1 to 8 and wherein each hydrogen atom on the alkylene group and on the phenyl groups can optionally be replaced by a substituent selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, and hydroxy groups. A particularly preferred compound is 1,3-(nitrooxymethyl)phenyl 2-hydroxybenzoate. The compounds are useful for treating and preventing various conditions, including coronary artery disease.

대표청구항 ▼

Nitric oxide donor compounds of the formula: are provided. In the formula, R is (CH2)n,wherein n ranges from 1 to 8 and wherein each hydrogen atom on the alkylene group and on the phenyl groups can optionally be replaced by a substituent selected from the group consisting of alkyl, cycloalkyl, hete

Nitric oxide donor compounds of the formula: are provided. In the formula, R is (CH2)n,wherein n ranges from 1 to 8 and wherein each hydrogen atom on the alkylene group and on the phenyl groups can optionally be replaced by a substituent selected from the group consisting of alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, halo, and hydroxy groups. A particularly preferred compound is 1,3-(nitrooxymethyl)phenyl 2-hydroxybenzoate. The compounds are useful for treating and preventing various conditions, including coronary artery disease. n the brain of the subject. 11. The method of claim 10 wherein the enantiomer is the R enantiomer. 12. The method of claim 10 wherein the enantiomer is the S enantiomer. 13. The method of claim 10 wherein the compound has the structure: 14. The method of claim 13 wherein the enantiomer is the R enantiomer. 15. The method of claim 13 wherein the enantiomer is the S enantiomer. 16. The method of claim 10 wherein the compound has the structure: 17. The method of claim 16 wherein the enantiomer is the R enantiomer. 18. The method of claim 16 wherein the enantiomer is the S enantiomer. 19. A method of treating a subject suffering from depression comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound having the structure: wherein when a is 0, b is 1 or 2; and wherein when a is 1, b is 1, m is 0-3, X is O or S, Y is halogeno, R1 is hydrogen or C1-4alkyl, R2 is hydrogen, C1-4alkyl, or optionally substituted propargyl and R3 and R4 are each independently hydrogen, C1-8alkyl, C6-12aryl, C6-12aryl or C6-12cycloalkyl, each optionally substituted, a racemic mixture, an enantiomer, or salt thereof, and a pharmaceutically acceptable carrier, to thereby treat the subject's depression. 20. The method of claim 19 wherein the pharmaceutically acceptable carrier is a solid and the therapeutically effective amount is an amount from about 0.5 mg to about 2000 mg. 21. The method of claim 19 wherein the pharmaceutically acceptable carrier is a liquid and the therapeutically effective amount is an amount from about 0.5 mg to about 2000 mg. 22. The method of claim 19 wherein the pharmaceutically acceptable carrier is a gel and the therapeutically effective amount is an amount from about 0.5 mg to about 2000 mg. 23. The method of claim 19 wherein the therapeutically effective amount is an amount from about 1 mg to about 1000 mg. 24. A method of selectively inhibiting monoamine oxidase-B (MAO-B) activity in the brain of a subject in need of such inhibition comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound having the structure: wherein when a is 0, b is 1 or 2; and wherein when a is 1, b is 1, m is 0-3, X is O or S, Y is halogeno, R1 is hydrogen or C1-4alkyl, R2 is hydrogen, C1-4alkyl, or optionally substituted propargyl and R3 and R4 are each independently hydrogen, C1-8alkyl, C6-12aryl, C6-12aryl or C6-12cycloalkyl each optionally substituted, a racemic mixture, an enantiomer, or salt thereof, and a pharmaceutically acceptable carrier, to thereby selectively inhibit MAO-B activity in the brain of the subject. 25. The method of claim 24 wherein the pharmaceutically acceptable carrier is a solid and the therapeutically effective amount is an amount from about 0.5 mg to about 2000 mg. 26. The method of claim 24 wherein the pharmaceutically acceptable carrier is a liquid and the therapeutically effective amount is an amount from about 0.5 mg to about 2000 mg. 27. The method of claim 24 wherein the pharmaceutically acceptable carrier is a gel and the therapeutically effective amount is an amount from about 0.5 mg to about 2000 mg. 28. The method of claim 24 wherein the therapeutically effective amount is an amount from about 1 mg to about 1000 mg.